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DNA methylation patterns are altered in numerous diseases 
and often correlate with clinically relevant information such as 
disease subtypes, prognosis and drug response. With suitable  
assays and after validation in large cohorts, such associations can 
be exploited for clinical diagnostics and personalized treatment 
decisions. Here we describe the results of a community-wide  
benchmarking study comparing the performance of all widely  
used methods for DNA methylation analysis that are compatible 
with routine clinical use. We shipped 32 reference samples 
to 18 laboratories in seven different countries. Researchers in 
those laboratories collectively contributed 21 locus-specific 
assays for an average of 27 predefined genomic regions, as  
well as six global assays. We evaluated assay sensitivity on low- 
input samples and assessed the assays’ ability to discriminate 
between cell types. Good agreement was observed across all  
tested methods, with amplicon bisulfite sequencing and bisulfite 
pyrosequencing showing the best all-round performance.  
Our technology comparison can inform the selection, optimization 
and use of DNA methylation assays in large-scale validation 
studies, biomarker development and clinical diagnostics. 
DNA methylation is an epigenetic mark widely studied for its associa-
tion with diseases such as cancer1 and autoimmune disorders2, with 
environmental exposures3 and with other biological phenomena4,5. 
Strong associations between DNA methylation patterns and clinical 
phenotypes can be used as biomarkers for diagnosing diseases and 
guiding treatment6,7. For example, DNA methylation biomarkers have 
been shown to support clinical decisions in various cancers8–14 and 
are also used for noninvasive prenatal testing15, for quality control of 
cultured cells16 and for forensic applications17,18.
DNA methylation biomarkers have several advantages that qualify 
them for broad use as in vitro diagnostics: (i) DNA methylation is 
cell-type-specific but robust toward transient perturbations, thus 
complementing static DNA-sequence-based biomarkers and volatile 
RNA-expression-based biomarkers. (ii) DNA methylation is a binary 
mark (i.e., for a single cell and allele, each CpG is either methyl-
ated or unmethylated), which facilitates reliable measurements on 
heterogeneous and degraded samples. (iii) The infrastructure for 
assaying DNA methylation biomarkers is already present in many 
clinical diagnostics laboratories, as the assays are similar to those 
used for DNA-sequence-based biomarkers. (iv) DNA methylation 
biomarkers are straightforward to integrate into routine clinical work-
flows because DNA is more stable than RNA and does not require 
any special handling. (v) DNA methylation patterns are faithfully 
retained during long-term storage as fresh-frozen or formalin-fixed, 
paraffin-embedded (FFPE) samples.
Genome-wide mapping and analysis of DNA methylation has 
become feasible for patient cohorts with thousands of samples19,20, 
and epigenome-wide association studies have been conducted 
for numerous biomedically relevant phenotypes21,22. To translate 
relevant epigenome associations into clinically useful biomarkers, it 
is necessary to select a manageable set of highly informative genomic 
regions, to target these loci with DNA methylation assays that are 
sufficiently fast, cheap, robust and widely available to be useful for 
routine clinical diagnostics23–25, and to confirm their predictive value 
in large validation cohorts.
Here we systematically compared and evaluated the most promising 
assays for measuring DNA methylation in large cohorts, clinical diag-
nostics and biomarker development. This multicenter study included 
research groups from seven countries across three continents, organized 
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by the BLUEPRINT project26 in the context of the International 
Human Epigenome Consortium27 and as a follow-up to a previous 
comparison of genome-wide DNA methylation assays28–30. Overall, 
our results show that most assays provide high accuracy and robust-
ness, although we observed some differences between assay types and 
laboratories. We provide detailed documentation of all contributed 
assays (Supplementary Data 1), such that this study can be used not 
only to guide assay selection but also as a resource of validated DNA 
methylation protocols.
RESULTS
Study design and assay selection
We selected assays based on comprehensive literature review, and 
for each promising assay we selected at least one research group that 
had extensive prior experience using that particular assay (Fig. 1a). 
In total, we invited 25 research groups, of which 19 agreed to partici-
pate. All participants received DNA aliquots for 32 reference samples, 
together with a list of 48 preselected genomic regions to be targeted. 
They designed the assays independently, analyzed the reference sam-
ples with their assays of choice and submitted the final results together 
with a detailed assay report for centralized benchmarking analysis by 
the study coordinator. Ultimately, 18 of the 19 participating research 
groups submitted complete analysis reports for a total of 27 assays 
(Table 1 and Supplementary Table 1). All contributed assays can be 
classified into one of three categories, which we summarize below.
First, absolute DNA methylation assays provide a quantitative meas-
ure of DNA methylation levels at single-CpG resolution. We included 
16 absolute assays based on four technologies: (i) amplicon bisulfite 
sequencing (AmpliconBS) uses next-generation sequencing (NGS) of 
pooled PCR amplicons derived from bisulfite-converted DNA31–33. 
(ii) Enrichment bisulfite sequencing (EnrichmentBS) is similar to 
AmpliconBS in its use of bisulfite conversion and NGS, but it uses 
highly scalable techniques such as padlock probes or microdroplet- 
based amplification to enrich many genomic regions in parallel 
rather than relying on separate PCRs for each individual region34,35. 
(iii) Mass spectrometric analysis of DNA methylation (EpiTyper) 
combines bisulfite conversion, in vitro transcription and uracil- 
specific cleavage with mass-spectrometry-based quantification of 
fragment lengths36–38. (iv) Bisulfite pyrosequencing (Pyroseq) applies 
sequencing by synthesis39 to single PCR amplicons obtained from 
bisulfite-converted DNA40,41.
Second, relative DNA methylation assays measure DNA methyla-
tion by comparing samples to a suitable reference. This approach is 
mainly used for detecting methylated DNA fragments in an excess 
of unmethylated fragments, but it also provides rough estimates 
of absolute DNA methylation levels. We included five relative 
DNA methylation assays based on three alternative technologies: 
(v) MethyLight uses PCR amplification of bisulfite-converted DNA 
in combination with fluorescently labeled probes that hybridize 
specifically to a predefined DNA methylation pattern, typically that of 
fully methylated DNA42,43. (vi) Methylation-specific melting assays, 
including methylation-sensitive high-resolution melting (MS-HRM) 
and methylation-specific melting curve analysis (MS-MCA), apply 
melting curve analysis to amplicons obtained from bisulfite-converted 
DNA, which provides a semiquantitative measure of cytosines that 
have been converted to thymines44–46. (vii) Quantitative methylation-
specific PCR (qMSP) uses DNA-methylation-specific primers in com-
bination with real-time PCR to compare the prevalence of a specific 
DNA methylation pattern with that of a suitable reference47,48.
Third, global DNA methylation assays measure a sample’s total 
DNA methylation content, which can be useful for measuring 
hypomethylation in cancer49 and the response to drugs that inhibit 
DNA methylation50. We included five global assays based on three 
alternative technologies: (viii) High-performance liquid chroma-
tography followed by mass spectrometry (HPLC-MS) quantifies the 
amount of 5-methylcytosine based on its mass difference compared to 
unmethylated cytosine51. (ix) Immunoquantification of global DNA 
methylation (Immunoquant) uses a modified enzyme-linked immu-
nosorbent assay (ELISA) with an antibody against 5-methylcytosine 
to quantify the total amount of methylated DNA in a given DNA 
sample52. (x) Bisulfite pyrosequencing of repetitive DNA elements 
(Pyroseq AluYb8/D4Z4/LINE/NBL2) applies pyrosequencing to 
amplicons obtained from bisulfite-converted DNA using primers that 
amplify multiple instances of the selected type of repeat53–56, which 
assumes that averaged local DNA methylation levels across specific 
repetitive regions correlate with global DNA methylation levels.
Given the study’s focus on clinically applicable assays, we did not 
include emerging technologies that have not yet been shown to be prac-
tically useful in large-scale studies, e.g., nanopores, nanowire transistors, 
quantum dots, single-molecule real-time sequencing and atomic force 
spectroscopy57. We also did not include genome-wide assays such as 
whole-genome bisulfite sequencing, reduced-representation bisulfite 
sequencing, methylated DNA immunoprecipitation sequencing or 
methyl-CpG binding domain enriched sequencing, given that these 
assays have been benchmarked previously28–30, and are currently too 
cumbersome and expensive for routine clinical diagnostics. However, 
we did include the Infinium 450k assay58, which we also used to select 
the target regions, and we performed a limited amount of clonal bisulfite 
sequencing59,60, given that this assay was until recently considered the 
gold standard but has been largely superseded by less labor-intensive 
assays. Our benchmarking did not explicitly address non-CpG methyla-
tion nor DNA methylation variants (5hmC, 5fC and 5caC), but most 
of the included assays can be used to measure non-CpG methylation as 
well as CpG methylation, and they can also be adapted to distinguish 
between DNA methylation variants61–63. Finally, we note that all contrib-
uted locus-specific assays were bisulfite-based, although we had invited 
four research groups that had expertise in alternative technologies.
Reference samples and target regions
We prepared 32 reference samples that mimic typical applications 
of DNA methylation assays in biomedical research and clinical 
diagnostics (Supplementary Table 2). This sample set included 
DNA extracted from six pairs of primary colon tumor and adjacent 
normal colon tissue samples (‘tumor/normal), DNA from two cell 
lines before and after treatment with a demethylation-inducing drug 
(‘drug/control’), a titration series with partially methylated DNA 
spiked into unmethylated DNA (‘titration 1’), another titration 
series with DNA from a cancer cell line spiked into whole blood DNA 
(‘titration 2’), and DNA from two matched pairs of fresh-frozen and 
FFPE xenograft tumors (‘frozen/FFPE’).
To establish suitable targets for the locus-specific assays, we per-
formed genome-scale DNA methylation analysis with the Infinium 
450k assay and selected 48 differentially methylated CpGs that cover 
a broad range of technical challenges encountered in biomarker 
development (Supplementary Table 3). For example, we included 
genomic regions with high and low CpG density, GC content and 
repetitive DNA overlap. As an additional challenge, we included a 
single-nucleotide polymorphism (SNP) that replaces a potentially 
methylated CpG by an always unmethylated TpG dinucleotide in 
some of the reference samples.
To each contributing laboratory we sent aliquots of ~1 µg DNA 
for each of the 32 reference samples. In addition, we provided a 
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standardized information package comprising general instructions, 
documentation templates and the list of the 48 target genomic regions 
(Supplementary Data 2). Each region had one designated target CpG 
for which the DNA methylation level was to be measured, and we 
asked the contributing research groups to return DNA methylation 
measurements for each of the reference samples. We gave no further 
instructions on how to design the assays or how to derive the DNA 
methylation measurements for the target CpG from the raw data. 
Moreover, we asked research groups not to exchange any information 
among each other, and they did not have access to the Infinium 450k 
data used for region selection.
We designated 16 of the 48 target regions as mandatory (‘core 
regions’) and let scientists in each contributing research group for 
themselves decide how many of the remaining 32 regions they would 
cover in addition to the core regions. On average, assay design was 
attempted for 30 genomic regions and was successful in 95% of cases 
(Supplementary Table 1). The known SNP at one of the target CpGs 
was detected and reported by 9 of the 17 research groups who con-
tributed locus-specific assays. We removed the SNP-containing region 
from further analysis to avoid bias, but we emphasize the importance 
of double-checking for known SNPs during assay design. In total, 
scientists from 18 laboratories contributed 16 absolute, 5 relative and 
6 global assays (Supplementary Fig. 1), giving rise to a benchmarking 
data set with 16,435 locus-specific and 192 global DNA methylation 
measurements (Supplementary Data 3).
Performance of absolute DNA methylation assays
All absolute assays detected the expected bimodal pattern of DNA 
methylation, with most regions being either highly or lowly methylated 
(Fig. 1b). NGS-based assays (i.e., AmpliconBS and EnrichmentBS) 
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Figure 1 Technology comparison of locus-specific DNA methylation assays. (a) Schematic overview of the study. (b) Distribution of measurements obtained 
with 16 absolute DNA methylation assays, plotted by assay (top), sample type (middle) and genomic region (bottom). Each point corresponds to one 
measurement for one genomic region in one sample. Point colors indicate assay technology, as defined in the top row. N, normal; T, tumor; D, drug-treated; 
C, control; F, fresh-frozen; P, FFPE. DNA methylation differences between sample groups were statistically significant (P < 0.001 for T/N, for D/C, and for 
the end points of the two titration series, P = 0.005 for F/P; two-tailed paired t-tests on M values). (c) Heatmap and hierarchical clustering of the Pearson 
correlation matrix for all assays across all DNA methylation measurements. (d) Scatterplots illustrating the correlation between the Pyroseq 1 assay and 
other selected assays across all reference samples and genomic regions. Blue lines indicate fitted linear models, and the reported numbers (r) are Pearson 
correlation coefficients. *, most similar to Pyroseq 1 (within each technology); #, least similar to Pyroseq 1 (across all technologies).
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reported extreme values of 0% and 100% more frequently than the 
other assays, which can be explained by their digital counting of meth-
ylated and unmethylated cytosines. The distribution plots confirmed 
the expected differences among the 32 reference samples (Fig. 1b), 
with higher DNA methylation levels for colon tumors than in matched 
normal tissue in the target regions, lower DNA methylation in the 
drug-treated leukemia cell lines, decreasing DNA methylation with 
decreasing concentrations of in vitro methylated DNA (titration 1) 
and cancer cell line DNA (titration 2), and similar DNA methylation 
levels for DNA extracted from fresh-frozen vs. FFPE xenografts. These 
plots also illustrate the broad range of different DNA methylation 
distributions among the selected target regions (Fig. 1b).
To assess global similarity among the absolute DNA methyla-
tion assays, we calculated Pearson correlation coefficients across 
all measurements for each pair of assays (Supplementary Fig. 2) 
and performed hierarchical clustering (Fig. 1c). 85% of between-
assay comparisons resulted in correlations above 0.8, and 46% even 
exceeded 0.9, indicating an excellent overall agreement between many 
of the tested assays. Correlations were high for technical replicates in 
the same laboratory (Pyroseq 1 vs. Pyroseq 1 (replicate): r = 0.996), 
the same technology between laboratories (e.g., Pyroseq 1 vs. Pyroseq 
2: r = 0.98) and between assays of different types (e.g., Pyroseq 1 vs. 
EpiTyper 3: r = 0.95; Pyroseq 1 vs. AmpliconBS 1: r = 0.97). However, 
not all assays agreed equally well (Fig. 1d and Supplementary Fig. 2). 
For instance, the Infinium assay reported higher DNA methylation 
levels for CpGs that other assays identified as lowly methylated, 
while reporting slightly reduced DNA methylation levels for highly 
methylated CpGs; and the EnrichmentBS 1 assay gave rise to 
a substantial number of outliers when compared to any of the 
other assays.
To quantify the accuracy of individual assays, a reference is needed 
against which to evaluate the measurements. Synthesized DNA with 
predefined DNA methylation patterns would be one option, but this 
is currently feasible only for fully methylated DNA spiked into fully 
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unmethylated DNA, thus ignoring the challenges posed by hetero-
geneous DNA methylation patterns64. For this reason, we chose two 
alternative approaches for quantifying assay performance in the pres-
ence of epigenetic heterogeneity.
First, we combined data from several assays into high-confidence 
consensus estimates to establish target DNA methylation levels for the 
reference samples (Fig. 2a and Supplementary Fig. 3a). For each sam-
ple and genomic region, we identified the smallest interval comprising 
measurements by at least three of the five technologies (AmpliconBS, 
EnrichmentBS, EpiTyper, Infinium and Pyroseq), which minimizes 
the impact of outliers and technology-specific artifacts. Moreover, we 
extended these intervals with flanking windows of five percentage points 
on either side to account for small deviations (Fig. 2a). We used the result-
ing ‘consensus corridor’ as a surrogate for the true DNA methylation 
level (which is unknown) of each target CpG in each reference sam-
ple. All assays contributed to the consensus corridor (Supplementary 
Fig. 3b,c), and sensitivity analysis confirmed that the ranking of assay 
performance was robust to the exact definition of the consensus 
corridor (Supplementary Note and Supplementary Fig. 4).
Evaluating each assay against this corridor (Fig. 2b and 
Supplementary Table 1), we observed the lowest mean absolute 
deviation for Pyroseq 1 and its replicate (1.1 and 1.2, respectively), 
closely followed by AmpliconBS 1 (1.6), Pyroseq 2 (2.5), AmpliconBS 
2 (2.8) and Pyroseq 5 (3.3). The highest mean absolute deviation was 
observed for EpiTyper 2 and EnrichmentBS 1 (6.8 and 11.4, respec-
tively). We also assessed the bias of each assay, which we defined as 
the directional (rather than absolute) deviation from the consensus 
corridor. For the Infinium assay we observed an overall tendency to 
over-estimate DNA methylation levels, whereas all Pyroseq assays 
tended to underestimate DNA methylation levels. For AmpliconBS 
EnrichmentBS, and EpiTyper, the average direction of the deviation 
depended on the laboratory.
Furthermore, to understand which properties make genomic 
regions difficult to measure, we fitted a linear model that predicts 
the deviation from the consensus based on each region’s estimated 
DNA methylation level, GC content, CpG observed vs. expected 
ratio and content of repetitive DNA (Supplementary Fig. 5). Four 
assays (AmpliconBS 4, EnrichmentBS 1, Pyroseq 4 and Pyroseq 5) 
showed significantly increased deviation in highly methylated 
regions, whereas the Infinium assay was comparably more accurate 
in highly methylated regions. GC content, CpG density and repeti-
tive DNA also affected the deviation in some cases, but the best- 
performing assays did not show any significant biases (Supplementary 
Fig. 5). Finally, we compared assay performance between matched 
fresh-frozen and FFPE samples (Supplementary Fig. 6). We obtained 
highly similar results, showing that all tested assays are compatible 
with DNA from FFPE material.
Second, as a complementary approach to consensus corridors, we 
assessed the performance of each assay using two titration series with 
known ratios. The titration samples included heterogeneous DNA 
methylation patterns, which make them more challenging than titra-
tions of fully methylated DNA used for assay calibration. For the first 
titration series, we created partially and heterogeneously methylated 
DNA by incomplete in vitro methylation (less than 20% methylated 
cytosines) and combined it with unmethylated DNA at ratios of 100%, 
75%, 50%, 10%, 1% and 0%. The second titration series mimics the 
diagnostic task of detecting hypermethylated cancer DNA against 
a background of blood-derived DNA. To that end, we spiked DNA 
from a colon cancer cell line (HCT-116) at ratios of 100%, 10%, 1%, 
0.1%, 0.01% and 0% into DNA extracted from whole blood. We then 
fitted linear models to the DNA methylation measurements (Fig. 2c 
and Supplementary Fig. 7) to assess consistency with the known 
titration ratios. The agreement was high for most assays and for 
three alternative metrics (Fig. 2d and Supplementary Table 1). Best 
results were achieved by AmpliconBS 1 with median Pearson correla-
tion coefficients of 0.99 and 0.93 in the two titration series (Fig. 2c). 
By contrast, EnrichmentBS 2 is an example of an assay that showed 
more variability with correlation of coefficients 0.77 and 0.87 (Fig. 2c). 
The results for the titration series were in good agreement with the 
assay performance in the consensus-based validation (Fig. 2b), with 
AmpliconBS 1, AmpliconBS 2, Pyroseq 1 and Pyroseq 3 being among 
the best in both analyses.
Finally, we assessed how clonal bisulfite sequencing59,60 would fare 
in our benchmarking, given that it was previously considered the gold 
standard for locus-specific DNA methylation mapping. At a target 
coverage of 10−20 Sanger sequencing clones, fully unmethylated and 
fully methylated CpGs gave rise to consistent measurements between 
replicates, but regions with intermediate DNA methylation levels 
agreed less well (Supplementary Fig. 8a). Diverging measurements 
appeared to be caused by random noise resulting from sequencing few 
clones, and both replicates clustered similarly well with other assays 
(Pearson correlation above 0.9 for all but one assay; Supplementary 
Fig. 8b). We did not observe any directional deviation from the 
consensus corridor (Supplementary Fig. 8c), and Pearson correla-
tion coefficients in comparison to other assays were in the range of 
0.7 to 0.9 in comparison to other assays (Supplementary Fig. 8d). 
Overall, clonal bisulfite sequencing performed reasonably well in our 
analysis but did not reach the accuracy and reproducibility of the 
top-ranking assays.
Performance of relative DNA methylation assays
Relative DNA methylation assays detect DNA molecules with a pre-
defined DNA methylation pattern, e.g., identifying fully methylated, 
tumor-derived DNA fragments in an excess of blood DNA. This 
approach is less suited for measuring quantitative DNA methylation lev-
els at single-CpG resolution, which prompted two of the research groups 
contributing relative assays to report their measurements as ranges 
(e.g., 0.1–1%, 1–10%, or 10–100%). Indeed, the observed correlations 
were generally lower for relative assays than for absolute assays, ranging 
from 0.5 to 0.7 in most comparisons (Supplementary Fig. 9).
To benchmark the relative assays in a way that accounts for their 
strengths and characteristics, we assessed their ability to detect differ-
ences in DNA methylation between pairs of samples. For each assay 
and each pairwise comparison we discretized the measurements into 
three categories (‘+’, higher DNA methylation in first sample; ‘−’, lower 
DNA methylation in first sample and ‘=’, no detectable difference) 
and calculated the agreement between the different assays (Fig. 3a). 
Percent concordance values were high for closely related assays (68% 
for MS-HRM vs. MS-MCA and 75% for qMSP preamp vs. qMSP 
standard), but substantially lower between technologies (Fig. 3b). 
Furthermore, when we compared these results with the concordance 
values observed for absolute assays using suitable thresholds (Online 
Methods), the relative assays were as similar to some of the absolute 
assays as they were to each other, but they did not reach the high 
concordance (90% and above) observed among the best-performing 
absolute assays (Fig. 3b).
We also assessed the discriminatory power of the relative assays 
for DNA methylation differences identified by the consensus cor-
ridor, and for the known ratios in the two titration series (Fig. 3c). 
In these analyses, all relative assays accurately detected DNA meth-
ylation differences that exceeded 25%, whereas the performance for 
smaller differences varied between assays. MethyLight and qMSP 
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detected many small differences with the expected direction, but 
reported the opposite direction for a considerable number of genomic 
regions. By contrast, MS-MCA and MS-HRM were more conservative 
and yielded very few mistakes regarding direction, but at the cost of 
detecting fewer differences.
Finally, we asked how well the relative DNA methylation assays cap-
tured quantitative differences in DNA methylation between samples. 
To that end, we took the quantitative differences reported by the rela-
tive assays for regions that were correctly classified and plotted them 
against the difference in consensus corridor estimates (Fig. 3d). The 
differences in the consensus corridor were most accurately recapitu-
lated by the MethyLight assay. By contrast, the measurements of the 
other relative assays did not correlate well with the difference obtained 
from the consensus corridor, supporting the notion that MS-MCA, 
MS-HRM and qMSP should only be used for the type of qualitative 
comparisons that they were originally developed for.
Finally, given that sample material is scarce in some applications 
of DNA methylation biomarkers (e.g., needle biopsies and blood- 
plasma-derived DNA), we also analyzed the effect of input DNA amounts 
on assay performance. This analysis confirmed that DNA amounts were 
not limiting the assay performance in the main part of our comparison, 
but only the AmpliconBS and Pyroseq technologies were able to cope 
with severely reduced amounts and/or high fragmentation of input DNA 
(Supplementary Note and Supplementary Figs. 10−12).
Performance of global DNA methylation assays
Global DNA methylation assays report a single measurement value for 
each sample, indicative of its total DNA methylation content (Fig. 4a). 
Absolute assay
for comparison
> 50
25–50
5–25
< 5
1 ↔ 0
10 ↔ 0
50 ↔ 0
75 ↔ 0
100 ↔ 0
0.01 ↔ 0
0.1 ↔ 0
1 ↔ 0
10 ↔ 0
100 ↔ 0
Titration 1
Titration 2
C
on
se
ns
us
 d
iff
er
en
ce
(p
er
ce
nt
ag
e 
po
in
ts
)
T
itr
at
io
n 
ra
tio
(p
er
ce
nt
ag
e 
po
in
ts
)
MethyLight MS-HRM MS-MCA qMSP (preamp) qMSP (standard)
Opposite Same No difference detectedDirection (in relative assay):
Number of observations
0 20 40 60 800 20 40 60 800 20 40 60 800 20 40 60 800 20 40 60 80
0 20 40 600 20 40 600 20 40 600 20 40 600 20 40 60
Pyroseq 1
MethyLight
MS-HRM
MS-MCA
qMSP (preamp)
qMSP (standard)
Consensus difference
0 25 50 75 100
Measured absolute difference
(percentage points)
> 50 25–50 5–25 < 5
c d
Not analyzed
a
= Concordance (%)
b
60
40
20
0
+
=
–
+
=
–
+
=
–
+
=
–
+
=
–
– – – – –= + = + = + = + = +
M
et
hy
Li
gh
t
M
S
-H
R
M
M
S
-M
C
A
qM
S
P
(p
re
am
p)
qM
S
P
(s
ta
nd
ar
d)
MethyLight MS-HRM MS-MCA
Frequency (%)
75 100250
EnrichmentBS 2
EpiTyper 2
Pyroseq 2
Pyroseq 3
Infinium
AmpliconBS 2
AmpliconBS 1
Pyroseq 1
Pyroseq 1 (replicate)
Pyroseq 4
EpiTyper 3
EpiTyper 1
Pyroseq 5
AmpliconBS 3
MethyLight
AmpliconBS 4
MS-HRM
MS-MCA
EnrichmentBS 1
qMSP (preamp)
qMSP (standard)
E
nr
ic
hm
en
tB
S
 2
E
pi
T
yp
er
 2
P
yr
os
eq
 2
P
yr
os
eq
 3
In
fin
iu
m
A
m
pl
ic
on
B
S
 2
A
m
pl
ic
on
B
S
 1
P
yr
os
eq
 1
P
yr
os
eq
 1
 (
re
pl
ic
at
e)
P
yr
os
eq
 4
E
pi
T
yp
er
 3
E
pi
T
yp
er
 1
P
yr
os
eq
 5
A
m
pl
ic
on
B
S
 3
M
et
hy
Li
gh
t
A
m
pl
ic
on
B
S
 4
M
S
-H
R
M
M
S
-M
C
A
E
nr
ic
hm
en
tB
S
 1
qM
S
P
 (
pr
ea
m
p)
qM
S
P
 (
st
an
da
rd
)
Worse Better
50
qMSP
(preamp)
qMSP
(standard)
0.00
0.00
0.39
0.02
0.22
0.22 0.22
0.21 0.21 0.01
0.01
0.01
0.01 0.35
0.11
0.14
0.29
0.02 0.26
0.07
0.01
0.21
0.05
0.04
0.14
0.16
0.09 0.33 0.07
0.05
0.25
0.13
0.18
0.26
0.31
0.08
0.020.14
0.17
0.16
0.22
0.17
0.18
0.00
0.21
0.14
0.00
0.00
0.00 0.00 0.00 0.00
0.00 0.00
0.00
0.000.00
0.03
0.24 0.10
0.000.00
0.00
0.60
0.000.25
0.00
0.00
0.02
0.08
0.03
0.02
0.14
0.00
0.13
0.01 0.01
0.01 0.01 0.01
0.010.07
0.05
0.11
0.03 0.03
0.220.14 0.240.05
0.16
0.16
0.00
0.00
0.26
0.17
0.03
0.21 0.01 0.02
0.36
0.09
0.09 0.16
0.16
0.14 0.04 0.13 0.18
0.18
0.03 0.34
0.10 0.500.230.320.050.290.260.070.35
0.10
0.08 0.31 0.26
0.00
0.00 0.00 0.00 0.00 0.00 0.00
0.000.00
0.00
0.02
0.02
0.08
0.21 0.00
0.00
0.19
0.06 0.38
0.00
0.57
0.00 0.24
0.00
0.00
0.00 0.00
0.00
0.000.03
0.18 
0.21 0.01 0.00
0.00
0.23
0.320.030.220.380.02
0.02
0.02 0.02
0.02
0.13
0.64
0.06 0.14
0.13
0.13 0.37
0.02
0.02
0.05
0.500.21
0.120.21
0.02
0.33
0.22
0.00
0.00 0.00
0.00
0.000.00
0.00
0.00
0.02
0.00
0.00
0.00
0.00
0.00
0.00
0.03
0.18
0.16
0.440.00 0.03 0.17 0.26
0.080.03 0.02 
0.02 
0.30
0.48 0.09
0.10
0.36
0.08 0.21
0.02
0.12 0.01
0.02 
1.00
1.00 0.72 0.74 0.77 0.81
0.740.72 0.67 0.77 0.77 0.77
0.770.770.661.000.720.72
0.67 0.74 0.66 1.00 0.77 0.83 0.82 0.82
0.860.890.881.000.770.770.77
0.81 0.76
0.76
0.83
0.82 0.89
0.88 1.00
0.91
0.91 0.92
0.92 0.92
0.91
0.86
0.83
0.83
0.83
0.83 0.86 0.87
0.80
0.82 0.80
0.80
0.85 0.72
0.69
0.69 0.75
0.69
0.71
0.70 0.68
0.64
0.68 0.69
0.64
0.66 0.55 0.52
0.49 0.62
0.62
0.630.540.570.670.660.700.730.69
0.69
0.60
0.64 0.62
0.66
0.70 0.71
0.55
0.70 0.62
0.58
0.63 0.67
0.67 0.53
0.51
0.58 0.50 0.61
0.610.49
0.47 0.53
0.61
0.62
0.500.42
0.510.52
0.470.57
0.68
0.660.60
0.61
0.570.58
0.65
0.630.67
0.64
0.64
0.70
0.660.820.82
0.82
0.700.66
0.80
0.640.600.690.69
0.83
0.85
0.85
0.870.80
0.80
0.690.690.69
0.80
0.820.70
0.710.73
0.66
0.740.73
0.79
0.70
0.70 0.66 0.58 0.75 0.69 0.71 0.73 0.70 0.66 0.62 0.67
0.63
0.64 0.64
0.65 0.58 0.52
0.52
0.52 0.53
0.53 0.52
0.55
0.55
0.28 0.36
0.470.440.440.68
0.42 0.35
0.35
0.350.35
0.40
0.44
0.44
0.44
0.44 0.42
0.400.470.36
0.28
0.55
0.680.530.53
0.52
0.52
0.55
0.620.50
0.42
0.47
0.570.68
0.52
0.51
0.620.610.53
0.47
0.53
0.670.64
0.51
0.49
0.610.61
0.50
0.58
0.670.67
0.57
0.54
0.630.620.62
0.49
0.53
0.640.66
0.55
0.52
0.610.55
0.39
0.52
0.620.62
0.63 0.630.58
0.44
0.47 0.470.52
0.53 0.56
0.610.60
0.50
0.47
0.69
0.53
0.46
0.66
0.75
0.75
0.620.50
0.700.550.710.700.690.560.700.620.500.630.67
0.57 0.56 0.55 0.59 0.68 0.64 0.68 0.66 0.63 0.58 0.62 0.60 0.61 0.57 0.50
0.67
0.61
0.71
0.72
0.72
0.76
0.820.85
0.84
0.530.46
0.64
0.830.850.820.80
0.84 0.83 0.85 0.84
0.760.82
0.82 0.80
0.81
0.81
0.941.000.920.92
0.91 0.92 0.94
0.80
0.82 0.83
0.84
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.83
0.86
0.79
0.83
0.860.820.790.780.75
0.77
0.71 0.76 0.74 0.69 0.83
0.810.760.760.750.73
0.79 0.80 0.83 0.86
0.61
0.53
0.500.47
0.56
0.69
0.81
0.76 0.700.69
0.74
0.76
0.71 0.73
0.75
0.76 0.74
0.73
0.72 0.71 0.67 0.61
0.70
0.66
0.58
0.67 0.57 0.62
0.60
0.61
0.62 0.52 0.39 0.55
0.630.560.47
0.52
0.47 0.44
0.53 0.63
0.58
0.56
0.55
0.59
0.63
0.50
0.62
0.700.79
0.73
0.71 0.69
0.66
0.79
1.00
0.77
0.77 0.77
0.74
0.79
0.800.79
0.76
0.76
0.78
0.750.71
0.71
Figure 3 Evaluation of relative DNA methylation assays. (a) Pairwise contingency tables for DNA methylation differences detected by the relative DNA 
methylation assays (‘+’, higher; ‘−’ lower; ‘=’,: similar). High values in the diagonal of any given 3 × 3 matrix are indicative of strong agreement between 
the corresponding pair of assays. (b) Clustered heatmap of the concordance (i.e., the sum of the diagonal divided by the sum of the 3 × 3 matrix) 
between all pairs of relative and absolute assays. Lighter colors indicate higher concordance. (c) Frequency of detecting the expected direction of DNA 
methylation difference for the relative assays evaluated against consensus corridor estimates (top) and the titration series (bottom). (d) Boxplots showing 
the quantitative differences reported by each relative assay (and by Pyroseq 1 as an example of an absolute assay), grouped by the consensus difference 
and focusing only on those genomic regions for which the direction was correctly identified by the relative assay (corresponding to blue bars in c).
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For HPLC-MS, the results were generally consistent with expecta-
tions, showing global hypomethylation for the tumor samples (as 
opposed to locus-specific hypermethylation in the target regions of 
the absolute and relative assays) and for the drug-treated cell lines 
(Fig. 4a), similar values for fresh-frozen and FFPE samples from the 
same xenograft, and gradually decreasing DNA methylation from 
left to right in the two titration series (with relatively small differ-
ences and one strong outlier). The data for the Immunoquant assay 
did not agree well with the characteristics of the reference samples. 
Finally, the pyrosequencing assays, which focused on different 
types of repetitive elements (AluYb8, D4Z4, LINE1 and NBL2), 
detected the drug-induced demethylation and, to a lesser extent, also 
the tumor hypomethylation (LINE1 and NBL2) and the differences 
in the titration series (NBL2).
With correlations of 0.37 to 0.82 between the three technologies 
(Fig. 4b), there was less agreement among the global DNA methyla-
tion assays than we had observed for the locus-specific DNA meth-
ylation assays. This result prompted us to explore whether global 
DNA methylation levels could be inferred from locus-specific data, 
as a potential alternative to measuring them with global assays. We 
defined the ‘global target’ as the outlier-corrected mean of the two 
best-performing global assays (HPLC-MS and Pyroseq NBL2), and 
we tested several approaches for predicting the sample-specific 
global target values from the locus-specific data. Averaging across 
locus-specific measurements did not provide an accurate prediction 
(correlations of 0.37 to 0.77, Fig. 4b), likely because the target regions 
were enriched for regulatory elements with different DNA methyla-
tion dynamics compared to the bulk of the genome. By contrast, 
machine learning methods such as the generalized linear model, sup-
port vector regression and random forest regression compensated 
for these differences and predicted the global target values much 
more accurately (Fig. 4c,d). These results suggest that locus-specific 
assays in combination with statistical methods can be used to detect 
sample-specific differences in global DNA methylation (Fig. 4e).
Accuracy and robustness as epigenetic biomarkers
Epigenetic biomarker development is an important application of 
DNA methylation assays, requiring robust discrimination between 
cell types or disease states. We observed good separation between 
the different cell types using unsupervised methods (Supplementary 
Fig. 13), and we sought to quantify the assays’ discriminatory power 
by supervised analysis focusing on the colon tumor and adjacent nor-
mal samples (Fig. 5). To that end, we trained support vector machines 
to distinguish between tumor and normal samples based on the data 
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Figure 4 Measurement and prediction of global DNA methylation levels.  
(a) Measurements obtained with six global DNA methylation assays in  
each of the 32 reference samples. To compensate for differences in the  
scale of reported values, all measurements are shown as percentages  
of the maximum value observed with each assay. Abbreviations are as in  
Figure 1. (b) Heatmap and hierarchical clustering of the Pearson correlation  
matrix of the global DNA methylation measurements across samples. The diagram also incorporates a consensus estimate of global DNA methylation 
(global target), which was calculated as the outlier-corrected mean of the measurements of the HPLC-MS and Pyroseq NBL2 assays. Mean DNA 
methylation levels are shown for each locus-specific assay, calculated across all covered genomic regions. (c) Cross-validated error (y axis) for predicting 
the global target of each sample from the data obtained with all locus-specific assays using different machine learning algorithms (x axis). Each data  
point is the prediction error of one regression method based on the data of one assay. (d) Cross-validated error (y axis) of the best-performing regression 
method (random forest regression) evaluated separately on data obtained with each of the 21 locus-specific DNA methylation assays (x axis).  
(e) Prediction of global DNA methylation levels in the reference samples, based on random forest regression trained on EpiTyper 2 data.
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of each assay. We used four tumor-normal pairs for training, and eval-
uated the prediction performance on test sets consisting of the two 
remaining pairs, constituting a threefold cross-validation. Receiver 
operating characteristic (ROC) curves show excellent prediction 
performance for most assays (Fig. 5a and Supplementary Fig. 14a), 
which is not unexpected because DNA methylation patterns are 
known to be different between colon tumor and adjacent normal 
tissue, and because we selected several target regions based on their 
differential DNA methylation in colon cancer.
To simulate the complications of working with clinical samples 
of varying quality, we added noise to the data and assessed how the 
prediction performance was affected. Two types of noise were intro-
duced (Online Methods): erroneous measurements were simulated 
by randomly replacing a fraction of DNA methylation measurements 
with other measurements (random error), and inaccurate measure-
ments were simulated by adding random noise to each measurement 
(uniform noise) (Fig. 5a,b). Using the ROC area under curve to 
assess performance, we found that low noise levels were well toler-
ated by all assays, but at higher noise levels some of the absolute assays 
(AmpliconBS 1, AmpliconBS 2, EpiTyper 1, EpiTyper 2 and Pyroseq 1) 
outperformed the other assays.
We also assessed the effect of reducing the number of genomic 
regions contributing to the analysis (Supplementary Fig. 14b). When 
we trained and evaluated each classifier on the one, three or five most 
discriminatory genomic regions at a constant level of 25% uniform 
noise (Fig. 5c,d), the prediction accuracy remained high for most 
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Figure 5 Discriminatory power of locus-specific DNA methylation assays. (a) Cross-validated performance of support vector machines discriminating 
between tumor and adjacent normal colon samples, based on DNA methylation values obtained with the best-performing assay (top) and worst-
performing assay (bottom). Shown are receiver operating characteristic (ROC) curves for classifiers trained on the actual data and on artificially noisy 
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curve) for support vector machines trained and evaluated separately based on data from each assay. The same error models were used as in a, and the 
performance was calculated separately for random error (left) and uniform noise (right). ROC curves are shown in Supplementary Figure 14a. (c) Cross-
validated prediction performance after restricting the data set to the most informative regions (top) or to randomly selected regions (random). ROC 
curves are shown for the best-performing assay (top) and worst-performing assay (bottom) at a constant level of 25% uniform noise. (d) Cross-validated 
ROC area under curve for each assay after restricting the data set to the most informative (left) or to randomly selected (right) regions. ROC curves are 
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assays (in some cases it even increased because the removal of less 
informative regions reduced noise in the data set). However, when we 
repeated the analysis with randomly sampled regions (Fig. 5c,d), we 
observed major differences: for many of those assays that performed 
well at high noise levels (Fig. 5b), the drop in performance was low, 
and satisfactory results were achieved using just three randomly 
selected regions. By contrast, other assays (in particular the relative 
DNA methylation assays) performed well only with combined data 
for many different genomic regions.
Finally, we selected two assays (EpiTyper 3 and Infinium) and tested 
their predictive performance on a much larger cohort comprising 
160 prostate tumor and 8 normal prostate samples. The concordance 
between the two assays was high for nine of ten tested CpGs, with 
Pearson correlations of 0.75 to 0.93, whereas one CpG showed little 
biological variation within the cohort and a low correlation coefficient 
(Supplementary Fig. 15a). When we trained and evaluated support 
vector machines for distinguishing between tumor and normal sam-
ples, we observed higher accuracy using the EpiTyper data than for 
the Infinium data, indicating that the locus-specific assays outper-
forms the Infinium assay in terms of accuracy and discriminatory 
power (Supplementary Fig. 15b).
DISCUSSION
We conducted a multicenter benchmarking study evaluating all DNA 
methylation assays that are strong candidates for clinical use. Most 
assays proved to be accurate and reproducible. The results also agreed 
well between laboratories and between technologies, which is nota-
ble because assay design (e.g., selection of primer sites and protocol 
parameters), execution (e.g., bisulfite conversion and sequencing) and 
data processing (e.g., normalization and quality control) were con-
ducted independently by members of each contributing laboratory. 
Overall, our study demonstrates that locus-specific DNA methylation 
assays can be considered a mature technology ready for widespread 
use in biomarker development and clinical applications.
Despite generally consistent results, we observed characteristic 
strengths and weaknesses of the tested assays. The relative assays 
were generally less accurate and less concordant with each other 
than the absolute assays. This observation is not unexpected given 
that relative assays work best for detecting fully methylated regions, 
whereas many of the selected target regions were heterogeneously 
methylated. Despite their lower quantitative accuracy, the relative 
assays distinguished robustly between methylated and unmethylated 
regions, and they discriminated well between tumor and normal 
samples. Among the global assays, the HPLC-MS measurements 
most accurately reflected the expected differences in global DNA 
methylation levels, whereas the Immunoquant assay did not provide 
reliable results. Bisulfite pyrosequencing of repetitive DNA gave rise 
to highly reproducible results, but these repetitive DNA methylation 
levels did not correlate well with the expected differences in global 
DNA methylation. By contrast, good results were obtained when pre-
dicting global DNA methylation from locus-specific measurements, 
which may become a viable alternative to measuring global DNA 
methylation directly.
To capture not only the quantitative performance but also other 
relevant aspects of each assay, members of the contributing laborato-
ries wrote detailed reports (Supplementary Data 1). These reports 
include protocol descriptions, comments on the practical strengths 
and limitations of each assay, and detailed time and cost calculations 
for running the assays in the respective laboratories. Drawing upon 
the cumulative experiences of our study, we arrive at the following 
conclusions and recommendations.
(i) Absolute DNA methylation assays are the method of choice when 
validating DNA methylation differences in large cohorts, and they are 
also an excellent technology for developing epigenetic biomarkers. 
(ii) Relative DNA methylation assays are not a good replacement for 
absolute assays. However, experiences of scientists in the contributing 
laboratories suggest that carefully selected, designed and validated 
relative assays can cost-effectively detect minimal traces of methyl-
ated DNA against an excess of unmethylated DNA. (iii) Global DNA 
methylation assays suffer from noisy data and divergent results 
between technologies. Locus-specific assays (possibly combined with 
prediction) provide a more robust alternative. (iv) Among the absolute 
DNA methylation assays, AmpliconBS and Pyroseq showed the best 
all-round performance, closely followed by EpiTyper. AmpliconBS is 
the best choice for assaying dozens of genomics regions in parallel, 
EpiTyper provides the highest sample throughput, and Pyroseq 
can work well even on minute amounts of highly fragmented DNA. 
(v) EnrichmentBS and Infinium can measure many more CpGs 
simultaneously than the other tested assays, but this comes at the 
cost of lower accuracy and higher cost per sample. (vi) Clonal bisulfite 
sequencing suffers from a high level of technical noise when sequenc-
ing 10−20 clones per sample. Given its high labor intensity and the 
availability of alternate assays with equal or better performance (as 
demonstrated in this study), clonal bisulfite sequencing is not recom-
mended for large-scale validation and biomarker development.
We conclude that the accuracy and robustness, discriminatory 
power, cost structure and practical feasibility of current DNA meth-
ylation assays are sufficient for large-scale validation studies and epi-
genetic biomarker development. We expect that DNA methylation 
assays will become widely useful for clinical diagnostics and per-
sonalized therapies, as companion diagnostics of targeted drugs, in 
forensic testing of tissue types and in many other applications. Our 
study may serve as a starting point for broader standardization efforts 
involving academic and clinical laboratories as well as the commercial 
sector and regulatory agencies, to fully embrace the potential of DNA 
methylation biomarkers for precision medicine.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. GEO: GSE77965.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
Preparation of reference DNA samples. Six pairs of fresh-frozen colon tumor 
and adjacent normal colon tissue samples were obtained from the IDIBELL 
Tissue Biobank following approval by the corresponding ethics committee. For 
DNA extraction, frozen tumors were incubated overnight at 37 °C with DNA 
lysis buffer (10 mM Tris pH 8.0, 100 mM NaCl, 10 mM EDTA pH 8.0, 10% 
SDS) and proteinase K, and phenol-chloroform extraction was carried out.
KG1 (ref. 65) and KG1a66 leukemia cell lines were obtained from the 
German Collection of Microorganisms and Cell Cultures (DSMZ). The cells 
were cultured in RPMI medium (Sigma-Aldrich) supplemented with 15% FCS 
(PAA) and 1% penicillin/streptomycin (Sigma-Aldrich) at 37 °C and 5% CO2. 
DNA demethylation was induced by treatment with 5-aza-2′-deoxycytidine 
(Sigma-Aldrich) at the half-maximal inhibitory concentration (IC50) deter-
mined by MTT viability tests for each cell line (80 nM for KG1 and 300 nM 
for KG1a). Stocks were prepared fresh for each experiment in 0.1% phosphate-
buffer-saline and kept at −20 °C until use. KG1 and KG1a cell lines where 
seeded in 75 cm2 tissue culture flasks (Sarstedt) at a concentration of 2.5 × 
105 cells/ml 24 h before treatment. Cells were treated for three days at 24-h 
intervals. Every 24 h, medium change was performed by centrifugation of cells 
at 900 r.p.m. for 5 min and resuspension of cell pellet in fresh warm medium. 
Cells were allowed to recover for 1 h before addition of the drug. Cells where 
harvested by centrifugation 96 h after seeding, and the cell pellet was washed 
twice with 1% PBS.
For the first titration series, the REPLI-g Whole Genome Amplification kit 
(Qiagen) was used to produce unmethylated DNA following the manufac-
turer’s protocol. Part of the whole genome amplified DNA was incompletely 
methylated in vitro using M.SssI (New England BioLabs) such that ~20% of 
all cytosines became methylated. For the second titration series, DNA was 
extracted from HCT-116 cells grown in vitro (as described below) and from 
whole blood of a healthy donor using GenElute Mammalian Genomic DNA 
Miniprep Kit (Sigma-Aldrich) according to the manufacturer’s protocol.
For the comparison of fresh-frozen and FFPE material, xenografts were pre-
pared as follows. Two colon cancer cell lines (HCT-15, derived from a Dukes’ 
type C colorectal adenocarcinoma, and HCT-116, derived from a colorectal 
carcinoma, both obtained from ATCC) were grown in DMEM with 10% FBS 
supplemented with antibiotic (37 °C, 5% CO2). Cells were harvested, filtered 
and aliquoted in PBS, and two SCID mice were subcutaneously injected in the 
flank with 3 × 106 tumor cells per animal and maintained over four weeks. 
Tumors were extracted, and each tumor was split in two. One part was formalin-
fixed and embedded in paraffin, whereas the other part was frozen at −80 °C. 
For the FFPE samples, DNA was extracted using the QIAamp DNA FFPE 
Tissue kit (Sigma-Aldrich) following the manufacturer’s protocol. DNA was 
resuspended in TE buffer pH 7.5 and treated with RNase (Sigma-Aldrich) for 
45min at 37 °C. DNA from the fresh-frozen samples was extracted in the same 
way as for the primary colon tumors.
All reference DNA samples were quantified using Qubit 2.0 (Invitrogen) and 
quality-checked by gel electrophoresis. Homogeneous aliquots of equal volume 
corresponding to a target DNA amount of 1 µg were prepared for all reference 
samples and shipped on dry ice to the contributing laboratories. Scientists 
in each laboratory confirmed DNA quality by gel electrophoresis and DNA 
amounts by one of four alternative technologies (Qubit, Quant-iT, NanoDrop, 
TapeStation), and the results in the analysis reports.
Selection of target genomic regions. To select informative and challeng-
ing target regions, we initially ran the Infinium 450k assay on all reference 
samples excluding the titration series and the FFPE samples. The resulting 
data were preprocessed and analyzed with RnBeads67, and we selected 1,072 
genomic regions (corresponding to 16 core regions, 32 additional regions, and 
1024 further regions for the EnrichmentBS assays) from the list of Infinium 
probes that passed quality control. Each of the regions was 122 base pairs 
wide, with the designated target CpG at the center and a window of 60 base 
pairs in both directions. 25% of these regions were selected based on differen-
tial DNA methylation for colon tumor vs. normal, 25% based on differential 
DNA methylation for drug treatment vs. control, 25% based on differential 
DNA methylated between the colon cancer cell lines and whole blood, and 
25% were randomly selected. Within each block of differentially methylated 
CpGs we selected: (i) a subset of the most strongly differentially methylated 
CpGs (ranks 1, 2, 3, 5, 7, 10, 13, 17, 21 and 25); (ii) the 1% highest and lowest 
regions in terms of repetitive DNA content, GC content, CpG content, CpA 
content and CpG observed vs. expected ratio; and (iii) the 1% CpGs with DNA 
methylation values in the first group that were closest to 0%, 25%, 50%, 75% 
and 100%, respectively. We also included CpGs in genomic regions that had 
previously been described as epigenetic biomarkers for colon cancer68. From 
this list of 1,072 genomic regions, we manually selected 16 core regions and 32 
additional regions such that the selected regions capture as much as possible 
of the technical challenges in assay design and analysis with locus-specific 
DNA methylation assays. One of the core regions (region 11) was chosen such 
that the target CpG overlapped with a common SNP, in order to provide an 
additional challenge during assay design. Furthermore, some of the remain-
ing 1,024 genomic regions were covered by the two assays that easily scale to 
hundreds of genome regions (EnrichmentBS 1 and EnrichmentBS 2). These 
measurements are available from Supplementary Data 3, but for reasons of 
comparability across assays they were not included in the benchmarking.
Documentation of DNA methylation assays, results and analysis workflows. 
The details for all contributed DNA methylation assays are available in 
Supplementary Data 1. These reports include a short assay summary, quality 
control data for the received reference DNA samples, and detailed descrip-
tions of the design and execution of each contributed assay. They follow the 
standardized reporting template from the information package that was sent 
to all contributing laboratories (Supplementary Data 2). DNA methylation 
measurements for each assay, genomic region and reference sample are avail-
able in Supplementary Data 3. Illumina 450k microarray data are available at 
the NCBI Gene Expression Omnibus under the accession number GSE77965. 
Finally, the source code (written in R) underlying the bioinformatic analysis is 
available in a public repository (http://biomarker-benchmark.computational-
epigenetics.org/), to foster transparency and reuse in the spirit of open science 
and reproducible research69.
bioinformatic analysis of absolute DNA methylation assays. To quantify 
assay performance without a priori knowledge of the true DNA methylation 
values in the reference samples, we defined target DNA methylation values 
by consensus. The consensus corridor was calculated as the narrowest inter-
val containing measurements from three different technologies, extended by 
an additional flanking region of five percentage points in both directions. 
We chose this corridor (rather than, e.g., the arithmetic or geometric mean 
between all measurements) to minimize bias toward overrepresented assays. 
Based on the consensus corridor we calculated the absolute difference |da,r,s| 
between the DNA methylation values va,r,s (as measured by an assay a for 
a region r in a sample s) and the closest boundary of the corresponding 
consensus corridor cr,s: |da, r, s| = va, r, s − cr, s. According to this metric, assays 
with smaller absolute differences are in better agreement with the consensus. 
To assess whether certain assays tend to systematically overestimate or under-
estimate DNA methylation values, we also calculated the directional deviation 
ba as the mean of all differences: 
b
d
R Sa
r R s S a r s=
×
∈ ∈Σ Σ , ,
| | | |
.
 
Finally, we performed a sensitivity analysis for the consensus corridor 
(Supplementary Note and Supplementary Fig. 4), which confirmed that 
our choice of parameters (i.e., using three different technologies and flanking 
regions of five percentage points to constitute the consensus corridor) was 
appropriate for robustly ranking the assays by their performance.
We also quantified the absolute assay performance in an alternative way, 
which does not rely on any consensus values but makes use of the two titra-
tion series. The DNA methylation values in both titration series are expected 
to be proportional to the titration ratios, which are known. In contrast, the 
DNA methylation values at the two extreme points of the titration series are 
different between regions and a priori unknown. Therefore, as outlined in 
Supplementary Figure 7, we first calculated the difference between the median 
of the consensus corridors for each titration series and each region at the 0% 
and 100% titration ratios. We then removed all regions that did not change by 
at least five percentage points to focus the analysis on regions with a clear-cut 
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change in DNA methylation over the titration series. Next, regions with a 
negative change between the 0% and 100% consensus values were inverted 
by subtracting their measured DNA methylation value from the maximum 
corresponding to complete DNA methylation. This procedure reversed direc-
tionality for the particular region and therefore standardized the direction 
across all regions. Finally, we adjusted for different offsets of DNA methylation 
levels by fitting a linear model to the values of each region and then subtracting 
the linear model offset (intersect) from these values. Using the adjusted DNA 
methylation values we then evaluated the Pearson correlation of the measured 
values to the titration ratios, which is the titration-based estimate of the correct 
value. To evaluate how well the assays captured the linearity of the DNA meth-
ylation values along the titration series, we also fitted a second intercept-free 
linear model to the adjusted DNA methylation values across all regions and 
samples, and we recorded the adjusted r2 and residual standard error of the 
fitted model. Assays with higher adjusted r2 values and lower residual standard 
error were considered in better agreement with the expectation that was based 
on the known titration ratios.
bioinformatic analysis of relative DNA methylation assays. We compared 
the relative assays among each other by calculating pairwise 3-by-3 contin-
gency tables for the differences between each pair of samples recorded by each 
assay. Measurements that agreed on the direction of change in both assays 
appear on the diagonal of the contingency table, and the higher the percent-
age of measurements on the diagonal, the more concordant both assays are. 
We formalize the agreement between assays as a numeric value, the percent 
concordance: 
A
c d
c
i j i j i j
i j i j
=
Σ Σ
Σ Σ
, ,
,
, 
where ci,j is the value in the ith row and jth column of the contingency 
table and 
d
i j
i ji j,
,
,=
=
≠



1
0
. 
This approach readily generalizes to the absolute assays, where we consid-
ered samples with an absolute difference of less than five percentage points 
as concordant.
In a separate and complementary analysis, we evaluated the ability of the 
relative assays to detect the correct direction of change between any two 
samples by using the median of the three DNA methylation values span-
ning the previously defined consensus corridor as reference. For each pair 
of samples, we determined the target direction and magnitude of change 
as the difference between the two median values, and we checked for each rela-
tive assay whether the difference between the corresponding measurements 
had the same or opposite direction of change. If no difference was detected 
in the relative assays, this was also recorded. The differences in the medians 
were divided into four bins: marginal change (absolute difference below five 
percentage points), small change (5−25 percentage points) medium change 
(25−50 percentage points), and strong change (above 50 percentage points). 
Finally, we also evaluated the relative assays based on the titration series, 
including only those regions with a difference above five percentage points 
between the two extreme points according to the consensus corridor. Results 
were regarded as consistent with the titration series if the direction of change 
observed for the relative assay was the same as the direction of the change 
in the titration ratio, taking into account the two extreme points according 
to the consensus corridor.
Correlation between input DNA amounts and assay performance.  
Two alternative approaches were used to assess the effect of DNA amounts on 
assay performance (Supplementary Note). First, owing to normal variation in 
the extracted DNA quality/quantity and in the initial quantification, the DNA 
amounts varied slightly between reference samples, e.g., ranging from 875 ng 
to 1,843 ng in the primary tumor/normal samples (Supplementary Fig. 10a). 
Each laboratory was provided with the exact same volume of homogeneous 
aliquots for these samples, such that these differences between samples did not 
result in differences between laboratories. To correlate input DNA amounts 
with assay performance, we fitted a linear model predicting the deviation 
from the consensus corridor for each sample and assay using two alternative 
measures of input DNA amounts: the first value based on the median of 
concentration measurements across all laboratories multiplied by the volume 
of DNA used for a given assay, and the second value based on the DNA amounts 
that each research group reported to have used according to their own con-
centration measurements. For each assay and each of the two measurements 
of DNA amount, P values were calculated with linear models and adjusted 
for multiple testing using the Benjamini-Hochberg method. We used an 
adjusted P-value threshold of 0.05 to call assays significantly influenced by 
DNA amount, but no associations were significant at this level.
Second, to assess the impact of DNA amounts in a much lower range (0.3 ng 
to 100 ng), we established a titration series with target DNA amounts of 
100 ng, 30 ng, 10 ng, 3 ng, 1 ng and 0.3 ng from one of the tumor reference 
samples (CRC 2 tumor). To exclude differences owing to variation among 
different bisulfite conversion protocols and reagents70, these samples were 
bisulfite-converted centrally, using the EZ DNA Methylation-Direct Kit (Zymo 
Research, D5020) with the following deviations from the manufacturer’s proto-
col: Conversion reagent was applied at 0.9× concentration, reactions incubated 
for 20 cycles of 1 min at 95 °C and 10 min at 60 °C, and the desulphonation 
time was extended to 30 min. The converted DNA was shipped on dry ice to 
nine laboratories that repeated their assays on these samples. We also analyzed 
the impact of reductions in DNA quality by fragmenting DNA from one of 
the tumor reference samples (CRC 1 tumor) to an average fragment 
length of 200 base pairs. To that end, batches of 600 ng DNA were digested 
with NEBNext dsDNA Fragmentase (New England BioLabs, M0348L) for 
exactly 60 min at 37 °C, stopping the fragmentation reactions by addition 
of 5µl 0.5M EDTA stop solution. The fragmented batches were combined, 
titrated to the same amounts as above, bisulfite-converted and shipped to the 
contributing laboratories.
Prediction of global DNA methylation levels. The global DNA methylation 
assays give rise to one single value per sample, which made it possible to plot 
all data points into one diagram (Fig. 4a) and to assess the overall consistency 
of the results by visual inspection. In addition, we explored whether we could 
predict global DNA methylation values from the results of the locus-specific 
DNA methylation assays, either by using the mean or median of the DNA 
methylation levels or by more complex machine learning methods such as 
generalized linear models, support vector regression (linear and polynomial 
kernels) and random forest regression. To compensate for the fact that not all 
assays were run on all samples, we first imputed missing values by filling in 
the values of the most closely related other assay based on Pearson correlation. 
We trained the regression models using leave-one-out cross-validation to make 
optimal use of the limited data set. For each method and each analysis, we 
recorded the root mean square error (RMSE) between the prediction and the 
target value. As no single global assay gave fully consistent results, we chose 
as global target the mean of the two best-performing assays (HPLC-MS and 
Pyroseq NBL2), and we replaced the four mean values that were inconsistent 
with the known change in concentration in the titration series by imputed 
values that were calculated as the mean of the two neighboring values in the 
titration series. The e1071 R package was used for support vector regression, 
randomForest for random forest regression and DMwR for cross-validation.
Analysis of discriminatory power. We trained linear support vector machines 
using patient-stratified cross-validation, such that each prediction used four 
tumor/patient pairs for training and left two pairs out for test-set validation. 
The e1071 R package was used to train the classifiers and the ROCR package71 
to calculate the ROC area under curve as the main performance metric. We 
further examined the robustness of the classifiers in presence of two different 
error models: (i) random error and (ii) uniform noise.
Random error. We simulated faulty measurements by replacing a defined 
fraction of measurements by random numbers drawn from the pool of all 
measurements of that assay. In this manner, we ensured that the simulated 
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erroneous measurements were drawn from the same distribution as the 
correct measurements without making assumptions about the statistical 
distribution of the data.
Uniform noise. We simulated inaccurate measurements by adding a ran-
dom number to each measurement. At any given noise level n, this random 
number was sampled uniformly from the interval [−n × r; n × r], where r is 
the range spanned by all DNA methylation values for the same assay. To 
assess the prediction performance, we tested each classifier in a stratified three-
fold cross-validation: for each error model, noise/error level, assay, and selec-
tion of training and test set, we performed 1,000 repetitions of the analysis with 
randomized noise/error. To assess the robustness toward fewer measurements, 
we repeated the analysis with 25% uniform noise after removing the majority of 
regions from the training and test sets. The choice of regions retained (either 1, 
3 or 5) was either entirely random or guided by the information content of each 
region for the prediction. We calculated the information content separately 
for each assay and region as the F score72. As before, we performed patient- 
stratified cross-validation with random repetitions. Finally, we analyzed a much 
larger cohort with 160 primary prostate tumor samples and 8 nonmatched 
normal prostate samples, comparing the EpiTyper 3 and Infinium assays with 
each other in terms of their correlation and discriminatory power.
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